Shire snaffles Dyax for $5.9bn plus kicker for HAE drug
Shire, the UK pharmaceutical company, has agreed to acquire US biopharmaceuticals company Dyax for $5.9bn in cash. Deutsche Bank and Morgan Stanley are arranging financing.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: